High-throughput in vitro hemotoxicity testing and in vitro cross-platform comparative toxicity.
For decades, hemotoxicity has been considered as simply changes in peripheral blood parameters or morphological changes observed in the bone marrow as a result of drug administration. The effects are actually the result of the drug acting at a much earlier level in the blood-forming system, usually at the level of the lympho-hematopoietic stem cell or its immediate differentiating progeny. To detect these early cellular responses, highly sensitive, non-subjective and fully standardized in vitro high-throughput testing platforms have been developed that detect changes in intracellular ATP concentrations which are directly proportional to and predict the proliferative/cytotoxic response of different cell populations.
Rich
Ivan N
IN
Chairman & CEO, HemoGenix, Inc., 4405 N. Chestnut Street, Suite D, Colorado Springs, CO 80907, USA. ivannr@hemogenix.com
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D016903:Drug Monitoring / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000139:chemically induced / Q000175:diagnosis; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007424:Intracellular Fluid / Q000187:drug effects / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D015203:Reproducibility of Results
D004364:Pharmaceutical Preparations; D000255:Adenosine Triphosphate